RxDoctor Payments Data

Ramon Ortega Colon, MD

Rheumatology · Carolina, PRNPI 1750386777

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,263 of the $6,121 with a category attached, or 86.0%. AbbVie accounts for 93.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,334 and has fallen 98.7% since, to $29 in 2025.

$6,121in general payments, 2019–2025

Across 19 payments — averaging $322.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • E.r. Squibb & Sons, L.L.C.$217
  • Amgen$97
  • Merck$36
  • GSK$29
$52,583in research payments, 2019–2025

Across 45 payments — averaging $1168.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$53K

What the payments were for

  • Consulting fees$5,26386%
  • Travel & lodging$130%
  • Food & beverage$84514%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$5,741
E.r. Squibb & Sons, L.L.C.3$217
Amgen1$97
Merck1$36
GSK2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,121 in reported general payments places this provider in the 70th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,096
Medicare patients
50
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept24$181,413
Humira PenAdalimumab25$174,884
Orencia ClickjectAbatacept26$149,727
EnbrelEtanercept17$127,992
OrenciaAbatacept13$74,863
ProliaDenosumab25$43,893
MethotrexateMethotrexate Sodium339$7,158
Hydroxychloroquine Sulfate125$4,884
Risedronate Sodium57$3,570
Sulfasalazine116$2,845
Prednisone373$2,216
Leflunomide17$1,680
Colchicine24$1,193
Diclofenac Potassium27$912
Methylprednisolone57$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia$97$171,88542 claims
E.r. Squibb & Sons, L.L.C.Orencia$217$74,86313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Carolina

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →